{"address1": "777 Old Saw Mill River Road", "city": "Tarrytown", "state": "NY", "zip": "10591-6707", "country": "United States", "phone": "914 847 7000", "website": "https://www.regeneron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.", "fullTimeEmployees": 15106, "companyOfficers": [{"maxAge": 1, "name": "Dr. Leonard S. Schleifer M.D., Ph.D.", "age": 71, "title": "Co-Founder, President, CEO & Co-Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 8184338, "exercisedValue": 0, "unexercisedValue": 400716864}, {"maxAge": 1, "name": "Dr. George D. Yancopoulos M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 7759830, "exercisedValue": 0, "unexercisedValue": 377769312}, {"maxAge": 1, "name": "Dr. Andrew J. Murphy Ph.D.", "age": 65, "title": "Executive Vice President of Research", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1680389, "exercisedValue": 21368200, "unexercisedValue": 106643088}, {"maxAge": 1, "name": "Mr. Daniel P. Van Plew", "age": 51, "title": "Executive VP and GM of Industrial Operations & Product Supply", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 2011227, "exercisedValue": 10666638, "unexercisedValue": 32363190}, {"maxAge": 1, "name": "Mr. Christopher R. Fenimore CPA", "age": 53, "title": "Executive VP of Finance & CFO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patrice  Gilooly", "title": "Senior Vice President of Quality Assurance & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  McCowan", "title": "Senior VP of IT & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Crowe", "title": "Senior Vice President of Investor Relations & Strategic Analysis", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph J. LaRosa J.D.", "age": 65, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1748110, "exercisedValue": 23227300, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Lozner", "title": "Senior VP & Chief Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://newsroom.regeneron.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 634.23, "open": 630.51, "dayLow": 615.18, "dayHigh": 640.99, "regularMarketPreviousClose": 634.23, "regularMarketOpen": 630.51, "regularMarketDayLow": 615.18, "regularMarketDayHigh": 640.99, "dividendRate": 3.52, "dividendYield": 0.57, "exDividendDate": 1740009600, "payoutRatio": 0.0, "beta": 0.268, "trailingPE": 16.101254, "forwardPE": 13.617303, "volume": 1059456, "regularMarketVolume": 1059456, "averageVolume": 952446, "averageVolume10days": 1001840, "averageDailyVolume10Day": 1001840, "bid": 585.37, "ask": 617.8, "bidSize": 2, "askSize": 1, "marketCap": 67453526016, "fiftyTwoWeekLow": 615.0, "fiftyTwoWeekHigh": 1211.2, "priceToSalesTrailing12Months": 4.7495794, "fiftyDayAverage": 681.8006, "twoHundredDayAverage": 891.8566, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 59960528896, "profitMargins": 0.3107, "floatShares": 102997343, "sharesOutstanding": 107508000, "sharesShort": 3249157, "sharesShortPriorMonth": 2204900, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0297, "heldPercentInsiders": 0.01578, "heldPercentInstitutions": 0.91378, "shortRatio": 3.59, "shortPercentOfFloat": 0.031400003, "impliedSharesOutstanding": 109325000, "bookValue": 273.566, "priceToBook": 2.255397, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.209, "netIncomeToCommon": 4412599808, "trailingEps": 38.32, "forwardEps": 45.31, "enterpriseToRevenue": 4.222, "enterpriseToEbitda": 12.956, "52WeekChange": -0.35117513, "SandP52WeekChange": 0.08089435, "lastDividendValue": 0.88, "lastDividendDate": 1740009600, "quoteType": "EQUITY", "currentPrice": 617.0, "targetHighPrice": 1152.0, "targetLowPrice": 575.0, "targetMeanPrice": 916.6296, "targetMedianPrice": 950.0, "recommendationMean": 1.84615, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 9012500480, "totalCashPerShare": 84.21, "ebitda": 4627999744, "totalDebt": 2938800128, "quickRatio": 3.86, "currentRatio": 4.731, "totalRevenue": 14202000384, "debtToEquity": 10.012, "revenuePerShare": 131.622, "returnOnAssets": 0.07314, "returnOnEquity": 0.15951, "grossProfits": 7099500032, "freeCashflow": 2635887616, "operatingCashflow": 4420499968, "earningsGrowth": -0.208, "revenueGrowth": 0.103, "grossMargins": 0.49988997, "ebitdaMargins": 0.32587, "operatingMargins": 0.26905, "financialCurrency": "USD", "symbol": "REGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Regeneron Pharmaceuticals, Inc.", "regularMarketChange": -17.22998, "regularMarketDayRange": "615.18 - 640.99", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 952446, "fiftyTwoWeekLowChange": 2.0, "fiftyTwoWeekLowChangePercent": 0.0032520324, "fiftyTwoWeekRange": "615.0 - 1211.2", "fiftyTwoWeekHighChange": -594.19995, "fiftyTwoWeekHighChangePercent": -0.49058783, "fiftyTwoWeekChangePercent": -35.11751, "dividendDate": 1742428800, "earningsTimestamp": 1745929800, "earningsTimestampStart": 1745929800, "earningsTimestampEnd": 1745929800, "earningsCallTimestampStart": 1745929800, "earningsCallTimestampEnd": 1745929800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 38.32, "epsForward": 45.31, "epsCurrentYear": 42.46885, "priceEpsCurrentYear": 14.5282955, "fiftyDayAverageChange": -64.8006, "fiftyDayAverageChangePercent": -0.09504333, "twoHundredDayAverageChange": -274.85663, "twoHundredDayAverageChangePercent": -0.30818477, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 670602600000, "preMarketChange": -0.10998535, "preMarketChangePercent": -0.017825827, "preMarketPrice": 616.89, "longName": "Regeneron Pharmaceuticals, Inc.", "corporateActions": [], "preMarketTime": 1743596303, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_33715", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "regularMarketChangePercent": -2.7166772, "regularMarketPrice": 617.0, "marketState": "PRE", "displayName": "Regeneron Pharmaceuticals", "trailingPegRatio": 0.9167}